Investigating the efficacy of integrating video-directly observed therapy (VDOT) in the treatment of tuberculosis (TB): A statewide analysis from Florida

IF 1.9 Q3 INFECTIOUS DISEASES
{"title":"Investigating the efficacy of integrating video-directly observed therapy (VDOT) in the treatment of tuberculosis (TB): A statewide analysis from Florida","authors":"","doi":"10.1016/j.jctube.2024.100471","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To determine if integrating VDOT into TB therapy demonstrated non-inferiority to direct observation, and if VDOT utilization increased across Florida after the onset of Covid-19.</p></div><div><h3>Methods</h3><p>A statewide programmatic review was conducted of all patients in Florida who initiated tuberculosis treatment between January 2018 – December 2018 and January 2020 – December 2021, as documented by the Florida Department of Health.</p></div><div><h3>Results</h3><p>1361 patients received treatment within the analysis timeframe. Therapy completion was 97.2% in those utilizing VDOT compared to 92.3% utilizing only DOT (<em>p=&lt;.001</em>). Average duration of therapy was 220.5 days in the DOT-only cohort compared to 211.1 days with VDOT integration (<em>p=.027</em>). A 176.35% increase in VDOT utilization was seen across Florida during Covid-19.</p></div><div><h3>Conclusions</h3><p>This is the first and largest state-wide study evaluating the efficacy of integrating VDOT into TB therapy, finding statistically significant improvements in completion and duration of therapy. Despite increased VDOT utilization since the onset of Covid-19, we suspect that multiple barriers may be hindering further integration. VDOT should be recommended as a cost effective, non-inferior alternative to DOT in monitoring the treatment of tuberculosis.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000585/pdfft?md5=53a81a011b7f7bc2a5244b626b2d383d&pid=1-s2.0-S2405579424000585-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579424000585","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To determine if integrating VDOT into TB therapy demonstrated non-inferiority to direct observation, and if VDOT utilization increased across Florida after the onset of Covid-19.

Methods

A statewide programmatic review was conducted of all patients in Florida who initiated tuberculosis treatment between January 2018 – December 2018 and January 2020 – December 2021, as documented by the Florida Department of Health.

Results

1361 patients received treatment within the analysis timeframe. Therapy completion was 97.2% in those utilizing VDOT compared to 92.3% utilizing only DOT (p=<.001). Average duration of therapy was 220.5 days in the DOT-only cohort compared to 211.1 days with VDOT integration (p=.027). A 176.35% increase in VDOT utilization was seen across Florida during Covid-19.

Conclusions

This is the first and largest state-wide study evaluating the efficacy of integrating VDOT into TB therapy, finding statistically significant improvements in completion and duration of therapy. Despite increased VDOT utilization since the onset of Covid-19, we suspect that multiple barriers may be hindering further integration. VDOT should be recommended as a cost effective, non-inferior alternative to DOT in monitoring the treatment of tuberculosis.

研究视频直接观察疗法(VDOT)在结核病(TB)治疗中的综合疗效:佛罗里达州的全州分析
目标确定将 VDOT 纳入结核病治疗是否显示出非劣于直接观察,以及在 Covid-19 开始后,佛罗里达州的 VDOT 利用率是否有所提高。方法对佛罗里达州卫生部记录的 2018 年 1 月至 2018 年 12 月和 2020 年 1 月至 2021 年 12 月期间开始接受结核病治疗的所有患者进行全州范围的项目审查。使用 VDOT 的患者治疗完成率为 97.2%,而仅使用 DOT 的患者治疗完成率为 92.3%(p=<.001)。仅使用 DOT 的患者平均治疗时间为 220.5 天,而使用 VDOT 的患者平均治疗时间为 211.1 天(p=.027)。在 Covid-19 期间,整个佛罗里达州的 VDOT 使用率增加了 176.35%。结论这是第一项评估将 VDOT 纳入结核病治疗的疗效的全州范围内最大规模的研究,发现在完成治疗和治疗持续时间方面有统计学意义的显著改善。尽管自 Covid-19 开始以来,VDOT 的使用率有所提高,但我们怀疑可能有多种障碍阻碍了进一步的整合。在监测结核病治疗方面,VDOT 应被推荐为一种具有成本效益且不劣于 DOT 的替代方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine
CiteScore
4.00
自引率
5.00%
发文量
44
审稿时长
30 weeks
期刊介绍: Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信